Stroke‐related mortality · asymptomatic carotid stenosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ipsilateral major or disabling stroke · asymptomatic carotid stenosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent ischaemic or unknown stroke during treatment period · acute presumed ischaemic stroke
Summary of findings table ‐ Anticoagulant probably leads to lower recurrent ischaemic or unknown stroke during treatment period compared with control (moderate certainty).
1 finding from 1 review
Stroke · people with antiphospholipid syndrome, with previous stroke
It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes stroke compared with single antiplatelet agent (very low certainty).
1 finding from 1 review
Stroke · people with antiphospholipid syndrome, with previous stroke
It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes stroke compared with dual antiplatelet agent (very low certainty).
1 finding from 1 review
Stroke · people with antiphospholipid syndrome, with previous stroke
It is very uncertain whether dual antiplatelet agent changes stroke compared with single antiplatelet agent (very low certainty).
1 finding from 1 review
Strokea · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
High‐dose VKA showed no clear difference in strokea compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Strokea · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
Standard‐dose VKA plus single antiplatelet agent showed no clear difference in strokea compared with standard‐dose VKA (low certainty).
1 finding from 1 review
Strokea · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
NOAC (rivaroxaban) probably leads to higher strokea compared with standard‐dose VKA (moderate certainty).
1 finding from 1 review
Intervention not reported
All strokes · people with atrial fibrillation deemed eligible for long‐term anticoagulant treatment
The intervention leads to lower all strokes (high certainty).
1 finding from 1 review
Intervention not reported
Stroke and other systemic embolic events · people with atrial fibrillation deemed eligible for long‐term anticoagulant treatment
The intervention leads to lower stroke and other systemic embolic events (high certainty).
1 finding from 1 review